Date |
|
Jan 5, 2016 |
CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial |
Jan 8, 2016 |
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum for 2016 |
Jan 14, 2016 |
CEL-SCI Corporation to Present at the Noble Financial Capital Markets’ 12th Annual Investor Conference |
Jan 25, 2016 |
CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine |
Feb 1, 2016 |
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial |
Feb 3, 2016 |
CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference |
Feb 8, 2016 |
CEL-SCI To Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference |
Feb 9, 2016 |
CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results |
Feb 18, 2016 |
CEL-SCI CEO Geert Kersten Was a Featured Guest on Fox Business’ Making Money with Charles Payne |
Feb 23, 2016 |
CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress in a New Video Interview |